viewVistry Group PLC

Bovis is heading in right direction but the stock is "still not cheap enough"

"We believe the new management team is taking the right steps to get Bovis closer to sector average returns. We see significant progress during FY17, and remain confident the 25% ROCE target by FY20E can be achieved," said UBS

A Bovis house
UBS believes the ground work for Bovis's operating margin to recover to the targeted 18.5% has been laid as long as the macro outlook remains stable

The new management of house-builder Bovis Homes Group PLC (LON:BVS) is taking the rights steps but the stock is not yet cheap, in UBS's view.

The Swiss bank has nudged up its price target to 1,090p from 1,080p, but that’s still comfortably below Bovis's share price of 1,174.5p and so the rating remains 'neutral'.

“In the context of an uncertain macro environment, we maintain our Neutral rating on Bovis as we see less execution risks elsewhere in the sector within the mid-cap space – we see a better risk-reward in peers such as Crest Nicholson, Bellway and Redrow, that are already delivering materially superior returns and at the same time trade on cheaper multiples,” UBS explained.

While many sector peers trade on cheaper earnings multiples, none can match Bovis's projected dividend yield of around 8% but “this is mostly due to £180mln of planned asset disposals being returned to shareholders”, UBS said.

“On other metrics, Bovis does not look cheap vs similar peers, even on more normalised levels (FY20) and considering higher execution risks,” UBS concluded.

Quick facts: Vistry Group PLC

Price: 1458 GBX

Market: LSE
Market Cap: £31.84 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



OptiBiotix Health agrees exclusive deal for LPLDL in USA and Canada

Steve Prescott, the chief executive of ProBiotix, which is a wholly-owned subsidiary of OptiBiotix Health PLC (LON:OPTI), caught up for a brief chat with Proactive London's Andrew Scott after announcing they've signed a distributor agreement with Advanced NutriSolutions Inc./Select Ingredient...

1 hour, 6 minutes ago

2 min read